Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

US Court of Appeals Affirms District Court Decision That Biogen's 2028 Tecfidera Patent is Valid

11/30/2021 | 11:12am EST


ę MT Newswires 2021
All news about BIOGEN INC.
04:26pBIOGEN : to Report Fourth Quarter and Full Year 2021 Financial Results February 3, 2022
PU
01/18Morgan Stanley Adjusts Price Target for Biogen to $360 From $363, Maintains Overweight ..
MT
01/18HC Wainwright Adjusts Biogen's Price Target to $270 from $452, Keeps Buy Rating
MT
01/18Biogen on Cusp of 'Change' in Wedbush View as Medicare's Proposed Plan for Alzheimer's ..
MT
01/14BofA Securities Adjusts Biogen's Price Target to $245 From $275, Maintains Neutral Rati..
MT
01/14California Court Of Appeal Affirms Injunction Barring Netflix From Poaching Fox Executi..
AQ
01/13S&P Downgrades Biogen Rating To 'BBB+' From 'A-' On Declining Sales, Lower Growth Prosp..
MT
01/13Biogen Wants Final Decision on Aduhelm Alzheimer's Drug to be 'Coverage With Restrictio..
MT
01/13Biogen eyes potential acquisitions - Stat News
RE
01/13Biogen Reportedly Works with Goldman to Explore Possible Acquisitions
CI
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 870 M - -
Net income 2021 1 727 M - -
Net Debt 2021 2 281 M - -
P/E ratio 2021 22,0x
Yield 2021 -
Capitalization 33 904 M 33 904 M -
EV / Sales 2021 3,33x
EV / Sales 2022 3,19x
Nbr of Employees 9 100
Free-Float -
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Last Close Price 230,81 $
Average target price 287,38 $
Spread / Average Target 24,5%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Mark Hernon Chief Information Officer & Senior Vice President
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Sector and Competitors